drugset / Trial / NCT01288157

A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects

NCT01288157

Phase 1 Completed 24 enrolled Centocor, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of golimumab in Chinese male participants.

Timeline

Start
2010-09
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Golimumab Monoclonal antibody 50 mg
Subject Golimumab Monoclonal antibody 100 mg

Indications

No indication recorded.